Prevalence and clinical profile of celiac disease in children with type 1 diabetes mellitus

Rajesh Joshi, Monica Madvariya
Department of Pediatrics, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India

ABSTRACT

Objective: To determine the prevalence of celiac disease (CD) in children with type 1 diabetes mellitus (TIDM) in follow-up in a Tertiary Care Referral Centre in Western India and to describe the clinical features indicative of CD in screened patients of TIDM.

Study Design: In this single center observational cross-sectional study, 71 children who were diagnosed with TIDM were subjected to screening for CD with tissue transglutaminase antibody testing. Those who tested positive were offered intestinal biopsy for the confirmation of diagnosis. Clinical profiles of both groups of patients were compared and manifestations of CD were delineated.

Results: The study revealed the prevalence of CD (based on serology) in children with Type 1 diabetes as 15.49%. The prevalence of biopsy-confirmed CD was 7.04%. Of the diagnosed CD patients, one-third were symptomatic at the time of screening while the majority was asymptomatic. The major clinical features indicative of CD were intestinal symptoms, anemia, rickets, and short stature. Autoimmune thyroid disease was prevalent in 29.6% of the patients with TIDM followed by CD. Conclusions: The high prevalence of CD in children with Type 1 diabetes emphasizes the need for routine screening programs to be in place for these high-risk populations. The clinical profile of patients with CD further elaborates the indicators of CD and the need to screen for them.

Key words: Celiac disease, children, tissue transglutaminase autoantibodies, Type 1 diabetes mellitus

INTRODUCTION

Owing to a common genetic background and interplay between environmental and immunologic factors, patients with Type 1 diabetes mellitus (TIDM) are at high risk of developing other autoimmune disorders. Studies have shown that 15–30% of patients with TIDM display Hashimoto’s thyroiditis, and celiac disease (CD) is the next in frequency after Hashimoto’s thyroiditis. Various studies have estimated that the prevalence of CD in TIDM varies from 3% to 16%, with a mean prevalence of 8%. The clinical picture of CD in TIDM is often silent with the absence of both gastrointestinal and extra-intestinal signs suggestive of gluten-sensitive enteropathy. Untreated CD may be responsible for malabsorption with relevant clinical manifestations (anemia, osteopenia, miscarriages, and liver dysfunction) and increased risk of complications (refractory CD, ulcerative jejunoileitis, and lymphoma). Hence, the International Society for Pediatric and Adolescent Diabetes recommends that serological screening for CD should be performed in all TIDM patients by means of antibodies to tissue transglutaminase (tTG IgA) at the onset of TIDM. Some authorities have recommended that not only symptomatic cases, but also even potential CD cases (diagnosed by serological testing but asymptomatic) should be kept on a gluten-containing diet with a careful

Corresponding Author: Dr. Monica Madvariya, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India. E-mail: minstream@gmail.com

Access this article online

Quick Response Code:
Website: www.ijem.in
DOI: 10.4103/2230-8210.167555

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Joshi R, Madvariya M. Prevalence and clinical profile of celiac disease in children with type 1 diabetes mellitus. Indian J Endocr Metab 2015;19:797-803.
clinical and antibody follow-up, since many of them will progress to develop villous atrophy and symptomatic CD on continued gluten exposure.\[1\]

Despite the advent of sensitive and specific serologic testing, routine screening for CD in diabetic populations is not a universal practice, especially in resource-limited settings. Though studies outside India\[6-12\] have suggested a high prevalence of CD in diabetics, the prevalence has not been extensively studied in India, especially in pediatric diabetic populations.

Furthermore, very few studies have been undertaken to delineate the manifestations of CD in diabetic children, which can be subtle (iron deficiency anemia, failure to thrive) yet can cause significant morbidity.

Therefore, this study was planned to examine the prevalence of CD in children with TIDM and identify the manifestations of CD in these patients.

**Materials and Methods**

**Study design and setting**

This was a single center observational cross-sectional study of children and adolescents aged 0–18 years diagnosed as TIDM, who were receiving insulin therapy. Children with type 2 diabetes or diabetes due to documented genetic defects in beta cell function or insulin action, pancreatitis, cystic fibrosis, and hemochromatosis were excluded from the study. The study was conducted in the Pediatric Endocrinology Clinic of a Tertiary Care Hospital in the Western India after approval by the Institutional Ethics Committee. Informed consent was taken from the parents as well as children over 7 years of age prior to enrollment in the study. The sample size in the study was 71 patients of Type 1 diabetes. All of these were screened for CD.

**Study procedure**

Each consenting patient was subjected to serologic testing for tTg IgA enzyme-linked immunosorbent assay (ELISA) using the same method and laboratory (EUROIMMUN anti-tTg IgA ELISA) each time. All patients with positive serologic test results were offered endoscopic intestinal biopsies to confirm CD. The histopathologic diagnosis of CD required jejunal or duodenal biopsy specimens with characteristic CD changes such as partial or complete villous atrophy associated with crypt hyperplasia and a lymphoplasmacytic infiltration in the lamina propria. The staging was done according to the Marsh classification.\[13\]

Furthermore, all patients were evaluated for clinico-epidemiologic features of CD at the time of serologic screening. This included detailed questioning regarding symptoms, physical examination, additional laboratory and radiologic testing, and evaluation for autoimmune thyroid disease (AITD) and glutamic acid decarboxylase antibody positivity. All patients with confirmed CD were recommended to go on a gluten-free diet and were managed appropriately for nutritional deficiencies. At the end of the study, the outcome measures were the prevalence of CD in children with Type 1 diabetes based on serology and histopathology and the prevalence and significance of association of the clinical features of CD.

**Statistical methods**

The prevalence of CD in TIDM cases was assessed using appropriate statistical methods. For comparisons between tTg IgA positive and tTg IgA negative groups, qualitative data were analyzed in the form of frequency and percentage and the association between discrete variables was assessed using Chi-square test and Fisher’s exact test. Quantitative data were represented by mean ± standard deviation and median.

**Results**

Out of 71 patients of TIDM, 11 tested positive for tTg IgA. Positive levels were defined as levels above 20 RU/ml. This translated into a prevalence of 15.49% of serology positive patients, irrespective of their symptoms or biopsy results. Out of six patients who consented for and underwent a biopsy, five had changes suggestive of CD, with a prevalence of 7.04% in the screened cohort.

Of the 11 serology positive patients, 54.5% were males and 45% were females. 36% of the serology positive patients were symptomatic at the time of presentation, while the majority (64%) was asymptomatic [Figure 1]. Table 1 depicts the symptomatology of CD patients.
Signs of malnutrition and micronutrient deficiencies
Failure to thrive was defined as weight Z-scores of the child falling below -2 for the age and sex, based on Agarwal charts. Short stature was defined as height for age Z-scores ≤ -2, based on Agarwal charts. Table 2 depicts the frequency of clinical signs in the CD group.

Laboratory features
Anemia was defined as hemoglobin concentration or red blood cell volume below the range of values in the normal population of the same age and sex, based on WHO definitions. Hypocalcemia was defined as a serum calcium level of less than 8.5 mg/dL. Hypophosphatemia was defined as serum phosphorus levels <3.8 mg/dL (1–3 years), 3.7 mg/dL (4–11 years), and 2.9 mg/dL (12–15 years).

High alkaline phosphatase was defined as alkaline phosphatase levels above 420 U/L (1–9 years) and above 560 U/L (10–11 years).

Radiological evidence of rickets/osteoporosis was looked for after obtaining wrist radiographs of all patients. Bone age was calculated for all the patients using the same hand radiographs, based on the Greulich and Pyle bone age atlas. Delayed bone age was defined as a lag of more than 2 years between the bone age and chronologic age.

25 OH Vitamin D levels were measured and were defined to be deficient below 15 ng/ml and insufficient between 15 and 20 ng/ml.

Thyroid function tests including free T3, free T4, and thyroid-stimulating hormone (TSH) as well as thyroid peroxidase (TPO) antibodies were done for all the patients. Overt hypothyroidism was defined as a TSH level of more than 4.5 µIU/L and a low free T4 level. Subclinical hypothyroidism was defined as TSH level >4.5 µIU/L with a normal T4 or free T4. High alkaline phosphatase was defined as Z-scores of the patients. Bone age was calculated for all the patients using the same hand radiographs, based on the Greulich and Pyle bone age atlas. Delayed bone age was defined as a lag of more than 2 years between the bone age and chronologic age.

25 OH Vitamin D levels were measured and were defined to be deficient below 15 ng/ml and insufficient between 15 and 20 ng/ml.

Thyroid function tests including free T3, free T4, and thyroid-stimulating hormone (TSH) as well as thyroid peroxidase (TPO) antibodies were done for all the patients. Overt hypothyroidism was defined as a TSH level of more than 4.5 µIU/L and a low free T4 level. Subclinical hypothyroidism was defined as TSH level >4.5 µIU/L with a normal T4 or free T4.

Table 3: Comparison of laboratory features in CD serology positive and negative patients

| Laboratory feature          | Number of patients (prevalence %) | Significance of association with CD |
|-----------------------------|-----------------------------------|------------------------------------|
| CD serology positive group  | CD serology negative group        |                                    |
| Anemia                      | 6 (54.5)                          | 12 (20)                            |
| Radiologic features of rickets | 5 (45.40)                       | 8 (13.3)                           |
| Hypophosphatemia            | 6 (54.50)                         | 8 (13.3)                           |
| Hypocalcemia                | 1 (9)                             | 1 (1.7)                            |
| High alkaline phosphatase   | 5 (45.40)                         | 27 (45)                            |
| Delayed bone age            | 2 (18)                            | 5 (8.3)                            |
| Vitamin D deficiency        | 5 (45.50)                         | 27 (45)                            |
| Hypothyroidism              | 3 (36.30)                         | 3 (5)                              |
| TPO antibody positivity     | 6 (54.5)                          | 15 (25)                            |

CD: Celiac disease

**Discussion**

This study concluded that the prevalence of CD in children with Type 1 diabetes was 15.49% (based on serology). The prevalence of biopsy-confirmed CD was 7.04%. In similar studies conducted in abroad and India, the prevalence...
of CD has ranged from 5.5% to 20% based on serology and 1.6% to 16.4% based on histopathology. The mean prevalence of histopathology proven CD based on these studies is 6.18%. Thus, we reported the prevalence of CD in T1DM close to the world mean prevalence, which is 8–10 times higher than the prevalence reported in the general population.

Most diabetic children with CD have silent or subclinical forms of the illness and only a small minority (48 of 400 in a recent meta-review) is identified by symptoms. In the various reports, the number of patients with symptoms and signs differ widely, which probably reflects how carefully these were sought. It is likely that some patients were regarded as asymptomatic when they were not. In our study, a third of the serology positive patients were symptomatic at the time of screening while the majority (64%) was asymptomatic.

Although intestinal symptoms are classical features of CD, they are more common in children diagnosed within the first 2 years of life. With the shifting of the age at the presentation of the disease later in childhood and with the wider and more liberal use of serological screening tests, extra-intestinal manifestations, without any accompanying digestive symptom, have increasingly been recognized, affecting almost all organs. Further, at the time of screening, most children do not complain of gastrointestinal disturbances, but failure to thrive and gastrointestinal symptoms may be present, and in some cases may only be recognized in retrospect.

In our study, intestinal symptoms (chronic diarrhea, chronic abdominal pain, and abdominal distension) indicative of CD were present in a third of the CD patients. Furthermore, there was clustering of all 3 symptoms in 3 out of 4 CD patients who reported this. Among extra-intestinal symptoms, the most common was a failure to gain height, followed by failure to gain adequate weight, and multiple fractures. No significant difference was found in those with or without CD in terms of these complaints.

**Failure to thrive**

Aktay et al. have reported growth failure in 11.7% of their CD patients. On the other hand, in a study by Westman et al., it was found that children and adolescents with coexisting T1DM and CD had normal growth, equivalent diabetes control and no differences in energy or nutrient intake compared to matched T1DM controls, despite only a 30% compliance to Gluten free diet. In our study, which evaluated patients using weight for age z-scores (prior to initiation of gluten-free diet), failure to thrive was not a significant clinical feature indicative of CD.

**Short stature**

Short stature has been reported in about one-third of children with CD in some series but others have reported that it is not a predominant feature. Rossi et al. reported the prevalence of CD among children with short stature as 1.7%. In an Australian study, no significant differences were found between Height z-scores of CD-T1DM patients and T1DM controls. Bhadada et al. reported that short stature was a manifestation in 52.3% of CD-T1DM patients. In our study, short stature was noted in 18.2% patients in CD patients as opposed to 10% patients in the CD serology negative group. This difference was not statistically significant. This was in contrast to the above cited studies which have reported short stature as the predominant feature of CD in T1DM. The possible explanation for this seeming contradiction was that the 4 patients with short stature in the CD serology negative group were labeled as Mauriac syndrome (trip of hepatomegaly, growth retardation, and cushingoid facies in poorly insulinized type 1 diabetes patients). One patient among the CD group was also suspected to have this syndrome. Thus, one fallacy of our study was that we could not eliminate confounding factors affecting growth like quality of glycemic control giving rise to this syndrome.

Delayed bone age was seen in two short-statured patients out of 11 CD patients (18.2%) while 8.3% of the serology negative patients had delayed bone age. This difference was statistically not significant.

**Anemia**

Anemia is a frequent finding in patients with CD and may be the presenting feature. Iron deficiency anemia is very common in the setting of CD and has been reported in up to 46% of cases of subclinical CD, with a higher prevalence in adults than children. In our study, 54.5% of CD patients had anemia compared to 20% in those without CD, which was found to be statistically significant. Of the CD group, all anemic patients were classified according to the WHO classification into the moderate category, while the anemic patients in the CD serology negative group presented a heterogeneous mix of mild/moderate/severe varieties (11.7%, 6.7%, 1.7%, respectively).

Microcytic anemia was most predominant (66.7% of the anemic patients) in the CD group, indicating it to be due to iron deficiency as a part of CD-malabsorption syndrome.

**Metabolic bone disease**

Metabolic bone disease in the form of rickets and osteomalacia in children and osteoporosis in adults is a prime feature of CD. The mechanisms postulated are not only malabsorptive-nutritional but also immunoregulatory
in nature.\textsuperscript{[39,40]} In our study, clinical evidence of rickets was present in 36.4% of CD patients as opposed to 13.3% in the CD serology negative group. We did not find a significant association between clinical evidence of rickets and CD. Overt hypocalcemia was not seen as a major manifestation in those with CD (9.1%). Hypophosphatemia was found to be significantly associated with CD serology positivity (54.5%). Though hypophosphatemia has not been reported previously as a major CD manifestation, its presence assumes significance as a biochemical manifestation of rickets in the CD patients. Radiologic evidence of rickets was another major manifestation of metabolic bone disease due to CD in this study (36.3%).

Despite Vitamin D deficiency being almost equally prevalent in both the groups (45% in both the groups), evidence of rickets and metabolic bone disease was more in the CD group. This could be due to the additional immunoregulatory mechanisms coming into play in patients with both CD and T1DM.

**Autoimmune thyroid disease**

AITD was detected on the basis of positivity for TPO antibodies in 54.5% among the CD group and 25% among the non-CD group. Overall, the prevalence of AITD in this cohort of type 1 diabetic children was 29.6%. Thus, AITD was the most common autoimmune disease found in our cohort of Type 1 diabetes patients. Overall, the prevalence of overt hypothyroidism was 8.4% while that of subclinical hypothyroidism was 11.26%.

**Intestinal biopsy**

Intestinal biopsy has been used as the gold standard for the confirmation of CD in all the studies cited, as well as in this study. However, we could biopsy only 6 patients out 11 as the rest were unavailable either because of attrition (lost to follow-up) or had not given consent to biopsy.

Among the 6 biopsied, 5 had biopsy changes suggestive of CD. Among the 5 not biopsied, 3 had very high tTG IgA levels, which were >10 times the upper normal limit. This was very suggestive of CD in these patients, even though not proven by biopsy.

This is now, especially, significant in the light of the new ESPGHAN guideline,\textsuperscript{[41]} which no longer holds intestinal biopsy as the gold standard for CD diagnosis. In contrast to the old guidelines, not only Marsh 3 lesions but Marsh 2 lesions are also accepted as compatible with CD. The reasoning behind this is that the histological features in CD may be patchy and, in a small proportion of CD patients, may appear only in the duodenal bulb, and hence can be missed. Furthermore, these alterations are not specific for CD and may be found in enteropathies other than CD.

**Limitations**

This study had limitations in terms of a smaller sample size, confounding factors such as glycemic control and nutritional intake and nonassent for intestinal biopsy by some serology positive patients. Furthermore, due to short-term follow-up of the study subjects (6 months–1 year) and attrition of subjects from tTg IgA positive group, we could not compare glycemic control, hypoglycemia, and other diabetes-related complications between the two groups.

**Conclusion and Clinical Implications of the Study**

- Children with type 1 diabetes and CD often do not have overt gastrointestinal complaints. They may be asymptomatic or may have these subtle manifestations: Iron deficiency anemia (especially, if refractory to therapy), rickets (unresponsive or partially responsive to Vitamin D), failure to thrive, short stature, pubertal delay; and frequent unexplained hypoglycemia episodes. All of these can be easily missed if not looked for. Because of the high prevalence and minimal symptomatology of CD in patients with type 1 diabetes, health care providers should have a low threshold for serologic screening for CD.
- Serologic evidence of CD is present in a high percentage of children at the time of diagnosis of Type 1 diabetes. Thus, screening for CD must be part of the standard of care for every newly diagnosed diabetic child.
- Dietary management of CD improves symptomatology, prevents hypoglycemia, and decreases the risk of osteopenia and malignant lymphoma.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Volta U, Tovoli F, Caio G. Clinical and immunological features of celiac disease in patients with type 1 diabetes mellitus. Expert Rev Gastroenterol Hepatol 2011;5:479-87.
2. Ventura A, Magazzù G, Gerarduzzi T, Greco L. Coeliac disease and the risk of autoimmune disorders. Gut 2002;51:897.
3. Frisk G, Hansson T, Dahlbom I, Tuvemo T. A unifying hypothesis on the development of type 1 diabetes and celiac disease: Gluten consumption may be a shared causative factor. Med Hypotheses 2008;70:1207-9.
4. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F; et al. Autoantibody “subspecificity” in type 1 diabetes: Risk for organ-specific autoimmunity
clasters in distinct groups. Diabetes Care 2005;28:850-5.

5. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. International Diabetes Federation; 2011. Available from: https://www.ispad.org/resource-type/idfispad-2011-global-guideline-diabetes-childhood-adolescence. [Last cited on 2015 Mar 30].

6. Boudraa G, Hachelaïf W, Benbouabdellah M, Bélkadi K, Benmansour FZ, Tronham M. Prevalence of coeliac disease in diabetic children and their first-degree relatives in west Algeria: Screening with serological markers. Acta Paediatr Suppl 1996;412:58-60.

7. Mahmud FH, Murray JA, Kudwa YC, Zinsmeister AR, Dierkhising RA, Lahr BD, et al. Celiac disease in type 1 diabetes mellitus in a North American community: Prevalence, serologic screening, and clinical features. Mayo Clin Proc 2005;80:1429-34.

8. Fröhlich-Reiterer EE, Hofer S, Kaspars S, Herbst A, Kordonouri O, Schwartz HP, et al. Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus—Data from a German/Austrian multicentre survey. Pediatr Diabetes 2008;9:546-53.

9. Salaridi S, Volta U, Zucchini S, Fiorini E, Maltoni G, Vaira B, et al. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: An 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr 2008;46:612-4.

10. Fallahi GH, Ahmadian JH, Rabbani A, Yousefnezhad AS, Rezaei N. Screening for celiac disease in diabetic children from Iran. Indian Pediatr 2010;47:268-70.

11. Djuric Z, Stamenkovic H, Stankovic T, Milicevic R, Brankovic L, Ciric V, et al. Celiac disease prevalence in children and adolescents with type 1 diabetes from Serbia. Pediatr Int 2010;52:579-83.

12. Bhadada SK, Kochhar R, Bhansali A, Dutta U, Kumar PR, Poornachandra KS, et al. Prevalence and clinical profile of celiac disease in type 1 diabetes mellitus in North India. J Gastroenterol Hepatol 2011;26:378-81.

13. Author Surname Initials (if available). Title of Website [Internet]. Place of publication: Publisher; Date of First Publication [Date of last update; cited date]. Available from: URL World Gastroenterology Organization Practice Guidelines: Celiac Disease; 2012. Available from: http://www.worldgastroenterology.org/assets/export/userfiles/2012_Celiac%20disease_long_FINAL.pdf. [Last cited on 2015 Apr 24].

14. Agarwal DK, Agarwal KN. Physical growth in Indian affluent children (birth-6 years). Indian Pediatr 1994;31:377-413.

15. WHO. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization (WHO/NMH/NHD/MMN/11.1); 2011. Available from: http://www.who.int/vmnis/indicators/hboglobin.pdf. [Last cited on 2015 Apr 26].

16. Kliegman RM, Stanton BF, St Gerne JW, Schor NF, Behrman RE, Nelson Textbook of Pediatrics. 20th ed. Philadelphia: Elsevier; 2015. p. 3467-72.

17. Misra M, Pscaut D, Petryk A, Collett-Solberg PF, Kapply M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Pediatrics 2008;122:398-417.

18. Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, et al. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium: Other complications and associated conditions with diabetes in children and adolescents. Pediatr Diabetes 2010;12:204-10. Available from: http://c.ymccdn.com/sites/www.ispad.org/resource/resmgr/ispad_CPCG_2009_-_CHAPTER_18.pdf. [Last cited on 2015 Apr 26].

19. Barera G, Bonfanti R, Viscardi M, Bazzigaluppi E, Calori G, Meschi F, et al. Occurrence of celiac disease after onset of type 1 diabetes: A 6-year prospective longitudinal study. Pediatrics 2002;109:833-8.

20. Tanteur MG, Silva IN, Bahia M, Penna FJ. Prevalence of celiac disease in Brazilian children with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2006;42:155-9.

21. Poulain C, Johansen A, Delcroix C, Lévy-Marchal C, Tubiana-Ruﬁ N. Prevalence and clinical features of celiac disease in 950 children with type 1 diabetes in France. Diabetes Metab 2007;33:453-8.

22. Fraser-Reynolds KA, Butzner JD, Brunter TL, Scott RB. Use of immunoglobulin A-antendomysial antibody to screen for celiac disease in North American children with type 1 diabetes. Diabetes Care 1998;21:1985-9.

23. Chan AW, Butzner JD, McKenna R, Fritzler MJ. Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients. Pediatrics 2001;107:88.

24. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Clinical proﬁle of coexisting conditions in type 1 diabetes mellitus patients. Ann Ital Med Int 2002;17:102-7.

25. Ergür AT, Oçal G, Berberoglu M, Adıyaman P, Sürlar Z, Aycan Z, et al. Celiac disease and autoimmune thyroid disease in children with type 1 diabetes mellitus: Clinical and HLA-genotyping results. J Clin Res Pediatr Endocrinol 2010;2:151-4.

26. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107:1538-44.

27. Koletzk S, Bürgin-Wolff A, Koletzk S, Bnpp M, Burger W. Prevalence of coeliac disease in diabetic children and adolescents. A multicentre study. Eur J Pediatr 1988;148:113-7.

28. Holmes GK. Celiac disease and Type 1 diabetes mellitus—The case for screening. Diabet Med 2001;18:169-77.

29. Troncone R, Auricchio S. Celiac disease. In: Wylie R, Hyams JS, editors. Pediatric Gastrointestinal and Liver Diseases. Philadelphia: Elsevier; 2006. p. 517-28.

30. Aktyan AN, Lee PC, Kumar V, Parton E, Wyatt DT, Werlin SL. The prevalence and clinical characteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr Gastroenterol Nutr 2001;33:462-5.

31. Westman E, Amler GR, Royle M, Peat J, Chan A. Children with coeliac disease and insulin dependent diabetes mellitus—Growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999;12:433-42.

32. Barera G, Bonfanti R, Viscardi M, Bazzigaluppi E, Calori G, Meschi F, et al. Occurrence of celiac disease after onset of type 1 diabetes: A 6-year prospective longitudinal study. Pediatrics 2002;109:833-8.

33. Hansen D, Bennedbaek FN, Hansen JK, Haier-Madsen M, Hegedii LS, Jacobsen BB, et al. High prevalence of celiac disease in Danish children with type 1 diabetes mellitus. Acta Paediatr 2001;90:1238-43.

34. Sivalahi E, Pelkonen P, Visakorpi JK. IgA deficiency in children. A clinical study with special reference to intestinal ﬁndings. Arch Dis Child 1971;46:665-70.

35. Corazza GR, Di Sario A, Cecchetti L, Lorizoz RA, Di Stefano M, Minguzzi L, et al. Inﬂuence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996;18:525-30.

36. Rossi TM, Albini CH, Kumar V. Incidence of celiac disease in pediatric patients. Pediatrics 2001;107:88.

37. Westman E, Amler GR, Royle M, Peat J, Chan A. Children with coeliac disease and insulin dependent diabetes mellitus—Growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999;12:433-42.

38. Corazza GR, Valenti RA, Andreani ML, D’Anchino M, Leva MT,
Ginaldi L, et al. Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. Scand J Gastroenterol 1995;30:153-6.
39. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 2002;25:1117-22.
40. Lorini R, Scaramuzza A, Vitali L, d’Annunzio G, Avanzini MA, De Giacomo C, et al. Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab 1996;9 Suppl 1:101-11.
41. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60.